Adma Biologics Charts Ambitious Growth Path Through 2029

Adma Biologics US0008991046

Presenting at the J.P. Morgan Healthcare Conference, Adma Biologics significantly upgraded its financial outlook, introducing detailed projections that extend to 2027 and establishing long-term targets for 2029. This move signals a potentially transformative phase for the company’s revenue and profitability.

On January 12, the company released preliminary, unaudited figures for 2025, reporting revenue of approximately $510–511 million. It also confirmed its adjusted net income and adjusted EBITDA for the year at $158 million and $235 million, respectively. A key highlight was the fourth quarter, which generated about $40 million in operational cash flow, contributing to a projected year-end cash position of roughly $88 million.